ARCHIVES

Phase III Nexavar Trial Fails Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

Research Integrity: Collins’ Student Falsified Data, ORI Finds

August 22, 1997

PRI’s Frederick Fee $903,866 For First Six Months Of New Contract

September 2, 1988

In Brief: ACCC Meeting Move To Jan. 31 In Jacksonville; ACS Gynecologic Cancer Meeting Sept. 18-20 In Phila.

August 22, 1975

Funding Opportunities

November 2, 2002

NCI Awards Regional CIS Contracts

August 6, 1993

Peer Review changes Urged By NIH Team Include Appeals

April 8, 1977